Join RoosterBio on Tuesday, August 23rd at 1:00 PM EST for our latest webinar: Translational Potential of hMSCs for Ocular Diseases. This seminar will be presented by Dr. Ali Djalilian, [….]
TTC is planning a technology opportunities webinar on July 13, 2021 from 11:00 am – noon, EST. Attendees will hear from the NCI’s Dr. Genoveffa Franchini about a new HIV [….]
NCI Technology Opportunities Webinar: “Complete Tumor Regression Seen in Colon Cancer and Leukemia Animal Models with a Novel High Efficacy Fluorinated Cytidine Therapeutic Compound”
The National Cancer Institute (NCI), Technology Transfer Center (TTC) will host a webinar to highlight a cancer therapeutic technology for collaborative development and/or licensing. The webinar presented by the technology inventor, Dr. Joel Morris, will highlight NCI’s novel, therapeutic fluorinated cytidine compound that shows high efficacy against colon cancer and leukemia. Studies indicated that the therapeutic compound can produce complete regression in xenograph mouse models with minimal effects on body weight. Registration is free.
In the BioHealth Capital Region, where reports are stating there are 2,000 current and projected open jobs within the biotech sector, the topic of attracting and retaining talent has never been more urgent. Some companies will adapt and succeed, while others will struggle to keep up. We want to help you and your company understand the challenges, take advantage of the opportunities, and succeed in growing your business, and the biotech community, in the BioHealth Capital Region.
Growing your business means aligning your executive team with your objectives. How do you know when new voices are needed? How do you recruit and retain the right voices?
NIH Technology Licensing Opportunity: A Novel Lymphatic/Brain Targeting Macromolecular Prodrug System
This webinar introduces a novel technology, a polymeric drug delivery platform that targets the lymphatic system and brain through scavenger receptor A1 (SR-A1) mediated transcytosis.
In an incredibly short time, Gaithersburg, Maryland’s Novavax has advanced its SARS-CoV-2 vaccine candidate into Phase III trials and received FDA fast track designation, putting its vaccine very close to potential FDA approval. There has been a herculean effort underway by Novavax and other companies to deliver desperately needed pandemic protection to people across the globe.
In seeking to combat emerging infectious diseases and other 21st-century health threats, the path to better prepared, protected, and healthy individuals, families, and communities could rely on unlocking the collective power of the global community. BLUE KNIGHT™ seeks to answer this call.
With cGMP facilities located in the U.S. and Europe, ABL is well-positioned to provide comprehensive development and manufacturing support for protein and virus production utilizing single-use bioreactor platforms and other disposable technologies.
Rockville, Maryland’s Advanced BioScience Laboratories, Inc. (ABL) is a rapidly growing, innovative, biotech company—a strategic viral GMP manufacturer and contract research organization with superb technical prowess. ABL is a CDMO and CRO providing GMP manufacturing and immunology solutions for gene therapies, oncolytics, vaccines, and other immunotherapeutics to biopharmaceutical, biotech, and life science organizations, and government agencies alike.